Search Results



  • The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System was developed by Purdue Pharma L.P. in 2001 as a way to address their risk management obligations, specifically the challenges they faced with reports of abuse, misuse and diversion of their product, OxyContin®.  

  • In 2006, the RADARS® System was acquired by Denver Health and Hospital Authority (DHHA) and became an independent, nonprofit operation of the Rocky Mountain Poison and Drug Center (RMPDC), a division of DHHA. 


  • The goal of the RADARS System is to provide surveillance data to meet the needs of pharmaceutical companies, policymakers, regulatory agencies, medical/public health officials and the public in addressing the concerns of prescription drug abuse.

  • The RADARS System is composed of seven programs (shown below), which target diverse populations throughout the United States. To validate and commend our data, the scientific advisory board (SAB) provides strategic direction and scientific interpretation of the data. 

  • The RADARS® System collects de-identified instances/reports of prescription drug abuse, misuse and diversion for specific drug products occurring in a three digit zip code. Rates of abuse in each three digit zip code then are calculated based upon population and drug availability. 


  • RADARS System data have been used by manufacturers, regulatory agencies and medical and public health officials to characterize and monitor prescription drug abuse, misuse and diversion. 

  • The data can be used for the submission of reports to the FDA (post market requirements and REMS evaluation), development of interventions, impact assessment of interventions (i.e. abuse deterrent formulations), monitoring the ever-changing market and publication assistance for technical reports, manuscripts and abstracts.